Emcure Pharmaceuticals Ltd (EPL) reported that it received an emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the introduction of Molnupiravir the oral anti-viral that is under investigation, to treat mild COVID-19.

Earlier this year, EPL was able to sign an agreement for licensing with Merck Sharpe Dohme (MSD) to produce and distribute Molnupiravir to India as well as over 100 countries of low and middle-income (LMICs). Molnupiravir is an oral anti-viral which blocks the replication of a variety of virus RNAs, including SARS-CoV-2 According to MSD.
https://microbiozindia.com/emcure-pharma-to-launch-oral-covid-19-dr...